An Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa

References

• Kirby JS. Qualitative study shows disease damage matters to patients with hidradenitis suppurativa. J Am Acad Dermatol. 2016;74(6):1269–1270. doi:10.1016/j.jaad.2016.01.001
   Web of Science ®Google Scholar
• Keary E, Hevey D, Tobin AM. A qualitative analysis of psychological distress in Hidradenitis Suppurativa.mBr. J Dermatol. 2019. doi:10.1111/bjd.18135
   Web of Science ®Google Scholar
• Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on quality of life and patient-oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019.
   Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/ced.1994.19.issue-3
   PubMed Web of Science ®Google Scholar
• Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169–180. doi:10.1111/j.1087-0024.2004.09113.x
   PubMed Web of Science ®Google Scholar
• Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–713. doi:10.1111/1523-1747.ep12365600
   PubMed Web of Science ®Google Scholar
• von der Werth JM, Jemec GB. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144:809–913. doi:10.1046/j.1365-2133.2001.04137.x
   PubMed Web of Science ®Google Scholar
• Onderdijk AJ, van der Zee HH, Esmann S, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2013;27(4):473–478. doi:10.1111/jdv.2013.27.issue-4
   PubMed Web of Science ®Google Scholar
• Kurek A, Johanne Peters EM, Sabat R, Sterry W, Schneider-Burrus S. Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges. 2013;11(8):743–9, 743–50. doi:10.1111/ddg.12067
   Web of Science ®Google Scholar
• Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in patients with hidradenitis suppurativa: a cross-sectional study using EuroQoL-5D. Acta Derm Venereol. 2016;96(2):222–226. doi:10.2340/00015555-2129
   Web of Science ®Google Scholar
• Matusiak L, Bieniek A, Szepietowski C. Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol. 2010;90:264–268. doi:10.2340/00015555-0866
   PubMed Web of Science ®Google Scholar
• Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232(6):687–691. doi:10.1159/000453355
   Web of Science ®Google Scholar
• Hamzavi IH, Sundaram M, Nicholson C, et al. Uncovering burden disparity: a comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol. 2017;77(6):1038–1104. doi:10.1016/j.jaad.2017.07.027
   Web of Science ®Google Scholar
• Kirby JS, Butt M, Esmann S. Jemec GBE association of resilience with depression and health-related quality of life for patients with hidradenitis suppurativa. JAMA DERMATOL. 2017;153(12):1263–1269. doi:10.1001/jamadermatol.2017.3596
   PubMed Web of Science ®Google Scholar
• Katoulis AC, Liakou AI, Rotsiamis N, et al. Descriptive epidemiology of hidradenitis suppurativa in Greece: a study of 152 cases. Skin Appendage Disord. 2017;3(4):197–201. doi:10.1159/000475822
   Web of Science ®Google Scholar
• Alavi A, Farzanfar D, Lee RK, Almutairi D. The contribution of malodour in quality of life of patients with hidradenitis suppurativa. J Cutan Med Surg. 2018;22(2):166–174. doi:10.1177/1203475417745826
   PubMed Web of Science ®Google Scholar
• Schneider-Burrus S, Jost A, Peters EMJ, Witte-Haendel E, Sterry W, Sabat R. Association of hidradenitis suppurativa with body image. JAMA DERMATOL. 2018;154(4):447–451. doi:10.1001/jamadermatol.2017.6058
   PubMed Web of Science ®Google Scholar
• Vinding GR, Knudsen KM, Ellervik C, Olesen AB, Jemec GB. Self-reported skin morbidities and health-related quality of life: a population-based nested case-control study. Dermatology. 2014;228(3):261–268. doi:10.1159/000358009
   Web of Science ®Google Scholar
• Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16(1):61–65. doi:10.1007/s40257-014-0105-5
   PubMed Web of Science ®Google Scholar
• Janse IC, Deckers IE, van der Maten AD, et al. Sexual health and quality of life are impaired in hidradenitis suppurativa: a multicentre cross-sectional study. Br J Dermatol. 2017;176(4):1042–1047. doi:10.1111/bjd.14975
   PubMed Web of Science ®Google Scholar
• Sampogna F, Abeni D, Gieler U, et al. Impairment of sexual life in 3485 dermatological outpatients from a multicentre study in 13 European countries. Acta Derm Venereol. 2017;97(4):478–482. doi:10.2340/00015555-2561
   PubMed Web of Science ®Google Scholar
• Kaaz K, Szepietowski JC, Matusiak Ł. Influence of itch and pain on sleep quality in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(8):757–761. doi:10.2340/00015555-2967
   Web of Science ®Google Scholar
• Sisic M, Kirby JS, Boyal S, Plant L, McLellan C, Tan J. Development of a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg. 2017;21(2):152–155. doi:10.1177/1203475416677721
   Web of Science ®Google Scholar
• McLellan C, Sisic M, Oon HH, Tan J. Preliminary validation of the HS-QoL: a quality-of-life measure for Hidradenitis suppurativa. J Cutan Med Surg. 2018;22(2):142–146. doi:10.1177/1203475417736281
   Web of Science ®Google Scholar
• Blanco R, Martínez-Taboada VM, Villa I, et al. Long-term successful adalimumab therapy in severe hidradenitis suppurativa. Arch Dermatol. 2009;145(5):580–584. doi:10.1001/archdermatol.2009.49
   PubMedGoogle Scholar
• Amano M, Grant A, Kerdel FA. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa. Int J Dermatol. 2010;49(8):950–955. doi:10.1111/ijd.2010.49.issue-8
   PubMed Web of Science ®Google Scholar
• Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–398. doi:10.1111/bjd.2011.165.issue-2
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Goussi C, Lallas A, Chovarda E, Apalla Z, Lazaridou E. Ioannides DA prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa. J Drugs Dermatol. 2012;11(5 Suppl):s15–s20.
   PubMed Web of Science ®Google Scholar
• AbbVie Ltd. A Phase 3 multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa – PIONEER I. Clin Study Rep Adalimumab Protocol. 2015.
   Google Scholar
• AbbVie Ltd. A Phase 3 multicenter study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa – PIONEER II (Clinical study report (Interim), adalimumab/protocol M11-810). 2015.
   Google Scholar
• Jemec GBE, Okun MM, Forman SB, ET AL. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. Br J Dermatol. 2019;181(5):967-975.
   Web of Science ®Google Scholar
• Zouboulis CC, Okun MM, Prens EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–69. doi:10.1016/j.jaad.2018.05.040
   PubMed Web of Science ®Google Scholar
• Kimball AB, Tzellos T, Calimlim BM, Teixeira HD, Geng Z. Okun MMAchieving Hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: post hoc analysis of pooled data from PIONEER I and II. Acta Derm Venereol. 2018;98(10):932–937. doi:10.2340/00015555-3012
   Web of Science ®Google Scholar